<DOC>
	<DOCNO>NCT01741519</DOCNO>
	<brief_summary>The study compare pharmacokinetics ( PK ) , safety tolerability long-term infusion lyophilize landiolol ( LDLL600 ) esmolol ( Brevibloc ) measurement blood concentration landiolol , esmolol metabolite , monitor systemic cardiovascular local tolerability , blood pressure ( BP ) , ECG include heart rate ( HR ) adverse event ( AEs ) .</brief_summary>
	<brief_title>Long-term PK Safety/Tolerability Testing LDLL600 Against Esmolol Healthy Volunteers</brief_title>
	<detailed_description>12 subject administer LDLL600 Brevibloc double-blind , randomize , cross-over setting . PK , systemic cardiovascular local tolerability safety 24-hour long infusion three dose level Investigational Medicinal Products ( IMPs ) treatment period assess . Each treatment period consist : Dose level 1 ( LOW ) 2 hour ( h ) Dose level 2 ( MEDIUM ) 2 hour Dose level 3 ( HIGH ) 2 hour PK tolerability observation dose level 3 , 2 1 continue 18 hour order end total infusion period 24 h Post-infusion follow-up ( FU ) 6 hour infusion termination The duration wash-out period treatment period least two day . Each subject , confirm eligible , complete two treatment period total . In case poor tolerability , alternative dosing scheme follow .</detailed_description>
	<mesh_term>Esmolol</mesh_term>
	<mesh_term>Landiolol</mesh_term>
	<criteria>Male female human subject , age 1845 year . Body weight least 50 kg , maximum 90 kg . Bodymass index 18.5 30.0 kg/m2 . Caucasian race . Subjects without clinically relevant abnormality determine baseline medical history , physical examination , blood pressure , heart rate ear temperature screen . Subjects without clinically relevant abnormality determine blood count , coagulation test , biochemistry ( except factor thrombophlebitis ) , infectious disease screening ( HIV , hepatitis B hepatitis C ) , urinalysis , ECG , 2D Echo screening . Subject willing able undergo procedure require protocol give write informed consent . Agreeing use prescription counter medication include vitamin mineral 7 day prior study course study ( unless prescribe principal investigator treatment adverse event ) . No history presence alcoholism . No history drug abuse ( benzodiazepine , barbiturate , cocaine ) last one month illegal drug last 6 month . Subjects condition opinion investigator make subject unsuitable inclusion . Subjects history presence clinically relevant cardiovascular , renal , hepatic , ophthalmic , pulmonary , neurological , metabolic , hematological , gastrointestinal , endocrine , immunological , psychiatric skin disease . Subjects bradycardia ( heart rate 50 bpm ) , tachycardia ( heart rate 100 bpm ) , hypotension ( systolic blood pressure 100 mmHg , and/or diastolic blood pressure 70 mm Hg ) screening , history clinically relevant arrhythmia . Subjects clinically relevant cardiac supraventricular ventricular arrhythmia . Subjects atrioventricular block grade II III , sick sinus syndrome , sinoatrial block congestive heart failure . Participation clinical drug study bioequivalence study 60 day prior present study . History malignancy serious disease . Any contraindication blood sample . History i.v . drug abuse . Subjects positive HIV test , HBsAg Hepatitis C test acute , subacute chronic infectious disease . Known history hypersensitivity landiolol , esmolol , relate drug . Refusal abstain smoke consumption tobacco product 48 hour drug administration study period . Refusal abstain alcohol , caffeine , xanthine , grapefruit contain food drink 72 hour drug administration study period . Refusal abstain strenuous activity 7 day screen endofstudy examination , study period . Found positive breath alcohol test do time screen day checkin study period . Found positive urine test drug abuse do day checkin study period . Subjects anomaly venous arterial vessel forearm systemic vascular disease . Subjects small and/or invisible and/or badly visible vein forearm . Pregnancy and/or breastfeed . History serious clinical illness impact fate drug . Use organ toxic drug within 3 month first dose . Any drug welldefined potential toxicity major organ system consider . Systemic multiple dose treatment drug alter hepatic metabolism monoamineoxidase ( MAO ) inhibitor within 30 day first dose . Donation 1 ) 400 mL blood within 60 day , 2 ) 150 mL blood within 30 day , 3 ) plasma platelet within 14 day first dose . Regular use medication except hormonal contraceptive replacement therapy ( HC HRT ) take without significant change three month least . Any systemic prescription drug treatment systemic overthecounter ( OTC ) drug treatment within 7 day first dose ( except HC HRT ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>PK</keyword>
	<keyword>PD</keyword>
	<keyword>landiolol</keyword>
	<keyword>esmolol</keyword>
	<keyword>healthy volunteer phase I study</keyword>
</DOC>